During induced hypotension with urapidil, measurements of intracranial pressure and of the ventricular volume-pressure response (intracranial compliance) were obtained in dogs with and without intracranial hypertension. A bolus of urapidil 50mg plus an infusion of urapidil 8.2±1.2mgmin~1 decreased mean arterial pressure by 22 ± 10% from control in group I (without intracranial hypertension) and by 24 ± 8% in group II (with intracranial hypertension). In both groups there was no change in intracranial pressure or in intracranial compliance after the administration of urapidil.
For more than a decade neurolept anaesthesia has been used during anaesthesia for neurosurgery in patients with intracranial space-occupying lesions (Fitch, Barker and Jennett, 1969; Michenfelder and Theye, 1971; Huse, 1977) . However, although the combination of neuroleptic agents, or benzodiazepines, with opiates, nitrous oxide and neuromuscular blockade provides satisfactory operating conditions, increasing doses of this combination cannot always prevent some manifestation of autonomic nervous system hyperactivity (Hamill et al., 1980; Davies, Cronin and Cowie, 1981; Ehehalt and Rupp, 1982; Kettler, 1982) .
In patients with intracranial space-occupying lesions sudden arterial hypertension can lead to impairment of the autoregulation of cerebral blood flow, and may initiate breakdown of the blood-brain barrier and a transudation of oedema fluid (Hulme and Cooper, 1972; Shapiro et al., 1972; Skinhoj and Strandgaard, 1973; Leech, Barker and Fitch, 1974) . Therefore, sudden increases in arterial pressure on intubation of the trachea, at the start of surgery and in the intensive care unit following operation should be avoided. Certain antihypertensive drugs such as sodium nitroprusside, nitroglycerine, hydrallazine and diazoxide increase intracranial pressure (ICP) by increasing cerebral blood volume and, as a result, cerebral perfusion pressure can be decreased markedly as a result of the simultaneous decrease in mean arterial pressure (MAP) and increase in ICP (Overgaard and Skinhoj, 1975; Cottrellet al., 1978; Cottrelletal., 1980; Gagnon and Shapiro, 1980; Van Aken, Puchstein and Hidding, 1982) . This study evaluates the effect of urapidil, a new selective postsynaptic alpha-adrenoceptor antagonist, on ICP and intracranial compliance (ICC) in dogs with, and without, intracranial hypertension.
MATERIALS AND METHODS
Studies were performed in 12 mongrel dogs of both sexes weighing 30.2 ±2.4 kg. The animals were premedicated with fentanyl 0.0075 mg kg" 1 and droperidol 0.375 mg kg" 1 i.v. Anaesthesia was induced with piritramide lmgkg" 1 i.v. and after the administration of pancuronium 0.1 mgkg" 1 i.v. the trachea was intubated with a cuffed orotracheal tube. Constant-volume, intermittent positive pressure ventilation (Respirator UV 1, Drager, Liibeck) was instituted at a rate of 10 b.p.m. with a mixture of 70% nitrous oxide in oxygen. The end-tidal carbon dioxide tension was maintained between 3.72 and 3.99 kPa, (infra-red carbon dioxide analyser: 47210 A Capnometer, Hewlett-Packard). Intermittent estimations of blood-gas tensions were obtained and AO2 maintained between 11.97 and 19.95 kPa. Anaesthesia and neuromuscular blockade were maintained with a continuous infusion of piritramide 15 mg h~' and pancuronium 2 mg h~' respectively. Temperature was maintained at 37 °C ± 1 °C using an electric heating pad. A balloon-tipped flowdirected pulmonary artery catheter was introduced through an internal jugular vein into the pulmonary artery. A femoral artery and vein were cannulated to permit monitoring of arterial pressure, and infusion Heart rates increased because of reflex stimulation, but the increases were not significant. In two dogs in group II distinct increases in heart rate were observed for a short period after the bolus of urapidil (97 to 157 beat min" 1 and 111 to 156 beat min" 1 ). This reaction to the vasodilator effect of urapidil had resolved 10 min after the administration of the bolus.
Since pancuronium, fentanyl, droperidol and piritramide were given during the whole experiment, we cannot exclude some influence of these agents on heart rate and arterial pressure. However, the baseline measurements and the measurements during urapidil were obtained under similar anaesthetic conditions. Therefore, it seems unlikely that the observed changes could be ascribed to the effects of these drugs.
Cardiac output remained unchanged throughout the procedure. The decrease in SVR paralleled the decrease in MAP (tables I and II). During the period of systemic hypotension there was no increase in ICP in either group ( fig. 1 ). In figure 2 the change in ICP after the rapid injection of saline lml into the ventricle before and after the administration of urapidil is shown. In neither group was there a change in the shape of the curve or in the absolute values of ICP after treatment with urapidil.
DISCUSSION
Urapidil is a new, recently introduced antihypertensive drug, which exerts central and peripheral actions. Sympathetic tone is decreased by activating central a 2 -adrenergic receptors and by stimulating terminal presynaptic 012-adrenergic receptors in the periphery. Additionally, urapidil inhibits the vasoconstricting effect of noradrenaline by blocking postsynaptic a r adrenergic receptors (Schoetensack etal., 1977) . On account of this blockade it has been used to treat .systemic hypertension during anaesthesia and in hypertensive crisis (Franke et al., 1980; Gless, Gram and Helmstadter, 1978) .
In our experiments we obtained a decrease in MAP of 22 ± 10% (group I) and 24 ± 8% (group II) primarily as a result of a decrease in afterload. ICP did not change during the hypotensive period in either group and since the other drugs received by the animals do not alter ICP markedly (Fitch, Barker and Jennett, 1969) , it is unlikely that any increase in ICP, as a result of the administration of urapidil, had been masked by a simultaneous decrease in ICP produced by the other drugs.
In neurosurgical patients, ICP may be normal, but intracranial compliance decreased, and some workers believe that the response of ICP to the injection of a small amount of fluid into the ventricle gives additional information about intracranial dynamics (Miller, 1975) . The VPR is a means of assessing the elastance and compliance of the intracranial contents (Langfitt, Weinstein and Kassell, 1965; Langfitt, 1980) . The initial steep increase in ICP after saline 1 ml relates to the elastance of the brain, since during the first 30 s after the injection there is no time for the cerebrospinal fluid, the primarily compliant system, to come into play (Langfitt, 1980) . The second part of the VPR curve, showing the decrease in ICP after the initial increase represents the compliance of the whole system. In neurosurgical patients ICP and intracranial compliance are important when considering the clinical relevance of an antihypertensive drug. With a decrease in intracranial compliance, small changes in intracranial dynamics can lead to dramatic increases in ICP.
In this study we found no change in either elastance or compliance in either group during the period of hypotension. The steepness of the volume-pressure curve, as defined by Langfitt, did not increase (Langfitt, Weinstein and Kassell, 1965) . This implies that the cerebrospinal fluid space, the intracerebral volume, and especially the intracerebral blood volume did not change. In contrast, nitroglycerine, sodium nitroprusside, hydrallazine and diazoxide, all increase ICP by expanding intracerebral blood volume. Thus urapidil appears to be a suitable antihypertensive agent with which to treat hypertensive episodes in neurosurgical patients (Overgaard and Skinhoj, 1975; Cottrell et al., 1978; Cottrell et al., 1980; Gagnon and Shapiro, 1980; Van Aken, Puchstein and Hidding, 1982) .
